S_nmary Syndecans are a family of cell-surface heparan sulphate proteoglycans which are involved in cell-matrix interactions and growth factor binding. Syndecan-1 binds basic fibroblast growth factor (bFGF) and several components of the extracellular matrix. Syndecan-l expression is induced dunng keratinocyte differentiation and reduced during the formation of squamous cell carinomas (SCCs). The purpose of this study was to examine the association of syndecan-l expression with prognostic factors and clinical outcome in SCC of the head and neck. Frozen sections of 29 primary SCCs were analysed for syndecan-l expression using immunohistochemical methods. Intermediate or strong staining for syndecan-l was associated with a smaler primary tumour size (P = 0.0005) and higher histological grade of differentiation (P = 0.006) than negative or weakly positive staining. In a univariate analysis, syndecan-l-positive tumours were associated with higher overall (P = 0.001) and recurrence-free survival (P = 0.003) than those tumours with no or little syndecan-l expression. The results suggest that syndecan-l could be an important prognostic factor of SCC of the head and neck. Further studies on the prognostic significance of syndecan-I expression in SCCs are warranted.
Cell adhesion molecules, such as integrins, cadherins and cell-surface proteoglycans, are involved in the regulation of cell differentiation, proliferation, morphology and migration (Gallagher, 1989;  Ruoslahti, 1991; Takeichi, 1991; Bernfield et al., 1992) . In the past few years it has become evident that this group of molecules working in concert is essential for the maintenance of normal cellular functions. The development of malignant epithelial tumours is associated with reduced intercellular adhesion, disturbed differentiation and changes in the composition of the basement membrane (Weinstein et al., 1976; Liotta et al., 1986) , suggesting that the expression and function of cell adhesion molecules could also change during malignant transformation. Indeed, alterations in the expression of many cell adhesion molecules associated with the development of carcinomas have been reported (Virtanen et al., 1990; Inki et al., 1991; Navarro et al., 1991; Schipper et al., 1991) .
Syndecans are a family of cell-surface heparan sulphate proteoglycans (HSPGs) which have been suggested to participate in cell-cell and cell-matrix interactions and the binding of growth factors (reviewed by Jalkanen et al., 1991 Jalkanen et al., , 1993 Bernfield et al., 1992) . The primary structure of the core proteins of four different syndecans, syndecan-l to syndecan-4, is known to date (reviewed by Bernfield et al., 1992) . All syndecans comprise an extracellular domain containing covalently linked heparan>sulphate chains, a transmembrane domain and a relatively short cytoplasmic domain Bernfield et al., 1992) . Syndecan-l has been shown to bind several extracellular matrix molecules via its heparan sulphate chains, including fibrillar collagens, fibronectin, thrombospondin and tenascin (Sun et al., 1989; Elenius et al., 1990; Salmivirta et al., 1991) . The localisation of syndecan-l on the surfaces of stratified epithelial cells (Hayashi et al., 1987) , as well as its expression in mesenchymal cell aggregates during organ development (Vainio et al., 1989) , suggests that syndecan-I could also play a role in cell-cell adhesion. Furthermore, syndecan-l can bind bFGF (Kiefer et al., 1990; Elenius et al., 1992) and present the growth factor to the signalling tyrosine kinase receptor system . Via binding bFGF, syndecan-l could be involved in the regulation of the angiogenic activities of bFGF (Folkman & Shing, 1992) and, in turn, neovascularisation during the development of malignant neoplasia.
During organ development, syndecan-I production is induced concomitantly with epithelial-mesenchymal interactions in a developmentally highly regulated fashion (Thesleff et al., 1988; Sutherland et al., 1991; Vainio & Thesleff, 1992) . In adult tissues, syndecan-I expression is almost entirely restricted to epithelial tissues, stratified epithelia containing the most abundant expression (Hayashi et al., 1987; Saunders et al., 1989) . In stratified epithelia, syndecan-l is localised over the entire surface of keratinocytes, especially in the suprabasal cell layers, whereas the basal cell layer shows modest expression (Hayashi et al., 1987; Inki et al., 1991) .
Syndecan-I expression is induced during the calcium-induced differentiation of cultured keratinocytes (Sanderson et al., 1992; Inki et al., 1994) , suggesting that syndecan-l may be involved in keratinocyte differentiation. However, during malignant transformation of keratinocytes syndecan-l expression is progressively lost from both premalignant epithelial lesions and SCCs (Inki et al., 1991 (Inki et al., , 1992a (Inki et al., , 1993 . In SCCs, syndecan-I is localised immunohistochemically in keratinising cells of the horn pearls in well-differentiated tumours, whereas poorly differentiated SCCs are devoid of syndecan-l (In.ki et al., 1992a syndecan-l (In.ki et al., , 1994 . In premalignant lesions of stratified epithelia, syndecan-I is lost from the basally located, atypical cell layers (Inki et al., 1991 Staining of syndecan-J Syndecan-l was localised in tissue sections using a polyclonal affinity-purified rabbit antibody (anti-PI17) described previously (Inki et al., 1994) . Anti-P117 was raised against a synthetic peptide corresponding to the cytoplasmic sequence of human syndecan-l and subsequently purified using a cyanogen bromide (CNBr)-activated affinity column coupled with the peptide (Inki et al., 1994) . Anti-PI 17 was shown to react specifically with syndecan-l in Western blot and immunohistochemical assays (Inki et al., 1994 
Results
Expression of syndecan-l in SCCs of the head and neck Syndecan-l was localised in frozen sections of SCCs of the head and neck using anti-PI 17 antibody and immunohistochemical methods. Anti-PI 17 has previously been shown to react specifically with the cytoplasmic domain of human syndecan-l core protein (Inki et al., 1994) . Staining intensity was compared with staining of normal epithelia from corresponding locations, which showed strong staining of keratinocyte cell surfaces (Figure la) . Seven (24%) SCCs showed negative ( Figure lb ) and ten (34%) weakly positive staining for syndecan-l (Table I) Intermediate or strong staining for syndecan-I was associated with small primary tumour size (P = 0.0005, Table  II ). However, no association between syndecan-l expression a and the presence of cervical nodal metastases was found ( Table IL) . Tumours that expressed syndecan-l (+ or + +) were more often well differentiated than those that did not express it (P =0.006, decan-1-positive tumour had a more favoura The difference in survival wassignicant both staining groups were compared with each oth and when tumours with strong syndecan-I ex or +) grouped together were compared wit negative (-or ±) tumours (Figure 2a , P = year survival rates for syndecan-I + +, + tumours were 80%, 80%, 30% and 0% respe year survival rate for tumours expressng synx + +, n=17) was 81 %, whereas that of tumours with no or weak expression (-or 4 only 18%. Similarly, patients with a tumour w expression had a higher recurrece-free surviF with a tumour with no or lttle syndecan-I exp survival 63% vs 18%, P=0.003, Figure 2b ).
Dis dss
We have previously shown alterations in the syndecan-I during malignant transformation. (Sanderson et al., 1992; mnuci et al., 1994) . Furthermore, syndecan-I is suppressed in malignant, poorly differentiated SCCs (Inci et al., 1991 (Inci et al., , 1992a (Inci et al., , 1994 , wheas positive expression is found in well-differentiated tumours (Inki et al., 1992a (Inki et al., , 1993 (Sorensen et al., 1989 (Wirnik et al., 1991) , its value has also been disputed by others (Dreyfuss & Clark, 1991; Bungaard et al., 1992; Trueson et al., 1992) . Our study showed a highly sificat association between syndecan-I ecpression and the prinary tumour size, which has prognstic value in a univariate survival analysis in the present series (P= 0.007) and many others (Bundgaard et al., b 1992; Cerezo et al., 1992) . In addition, syndecan-l expression was associated with the patients' WHO (Carter, 1991) . 
